Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RORC | P51449 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13324885 | 0.88 | MEN1 (0.41) | MEN1ALDH1A1KMT2AROCK2CYP3A4 | |
| SCHEMBL22593414 | 0.84 | CHRNB2 (0.42) | MEN1ALDH1A1KMT2APOLBNPC1 | |
| SCHEMBL17708305 | 0.79 | CYP1A2 (0.52) | ALDH1A1TP53HSD17B10NPC1 | |
| SCHEMBL17708306 | 0.79 | CYP1A2 (0.52) | ALDH1A1TP53HSD17B10NPC1 | |
| SCHEMBL7904346 | 0.79 | CYP1A2 (0.52) | ALDH1A1TP53HSD17B10NPC1 | |
| SCHEMBL3298525 | 0.78 | MMP1 (0.44) | MEN1ALDH1A1KMT2ATP53MMP1 | |
| SCHEMBL1417346 | 0.78 | MMP1 (0.44) | MEN1ALDH1A1KMT2ATP53MMP1 | |
| SCHEMBL3288873 | 0.78 | MMP1 (0.44) | MEN1ALDH1A1KMT2ATP53MMP1 | |
| SCHEMBL22025301 | 0.77 | MEN1 (0.35) | MEN1ALDH1A1KMT2AROCK2CYP3A4 | |
| SCHEMBL18029824 | 0.77 | GNAI3 (0.39) | MEN1ALDH1A1KMT2AROCK2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190127375-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127375-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | MEN1 1015/4885ALDH1A1 2706/4885KMT2A 1448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.